Morgan Stanley Maintains Underweight on Bristol-Myers Squibb, Lowers Price Target to $50
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Terence Flynn has maintained an 'Underweight' rating on Bristol-Myers Squibb (NYSE:BMY) and lowered the price target from $56 to $50.
October 27, 2023 | 12:54 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Morgan Stanley has maintained an 'Underweight' rating on Bristol-Myers Squibb and lowered the price target from $56 to $50.
The 'Underweight' rating and lowered price target by Morgan Stanley indicates a bearish outlook for Bristol-Myers Squibb. This could potentially lead to a decrease in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100